A new WWARN study has found that nearly two-thirds of the malaria-positive patients who present to health facilities are systematically excluded from “classical” anti-malarial treatment efficacy trials.

The three presentations and expert discussion, chaired by Professor Sir Nicholas White (Mahidol Oxford Research Unit) and Dr Chau Nguyen Hoang (Oxford University Clinical Research Unit), are now available on our YouTube channel @IDDOandWWARN. You can watch the full, partially captioned event here. ...

Two new studies using WWARN-hosted clinical trial data show that the dosing of the 8-aminoquinoline drugs primaquine and tafenoquine can be substantially improved. These analyses include the majority of all studied vivax malaria patients who received 8-aminoquinoline drugs over the last 20 years. La...

Read more about what we’ve been up to in our latest newsletter. There are updates on our research across COVID-19, malaria, medicine quality, febrile illness, Visceral leishmaniasis and you can sign up for our February 3 webinar - Radical cure of vivax malaria: can we do better?

A recent multidisciplinary pilot study, originating from LOMWRU and the Medicine Quality Research Group of IDDO and MORU, investigated whether bacterial, plant, fungal and animal DNA in the ingredients and from the environment (eDNA) could be detected from falsified (aka counterfeit) tablets.

Find out more about what we’ve been up to in our latest newsletter. You’ll find all of our news including our recent collaborative meta-analysis, commissioned by the WHO, which informed a change to its guidelines for treating uncomplicated malaria in the first trimester of pregnancy.

The number of studies reporting antimicrobial resistance (AMR) data has increased in Africa, South and South East Asia according to new research in the International Journal of Infectious Diseases.

Two new studies using WWARN-hosted clinical trial data show that the dosing of the 8-aminoquinoline drugs primaquine and tafenoquine can be substantially improved. These analyses include the majority of all studied vivax malaria patients who received 8-aminoquinoline drugs over the last 20 years. La...

A new WWARN meta-analysis commissioned by the World Health Organization (WHO) which informed a change to its treatment guidelines* has been published in The Lancet. The study provides compelling evidence that artemether-lumefantrine should now replace quinine as the treatment of choice in the first ...

IDDO’s Director Professor Philippe Guérin has been awarded the ASTMH Distinguished International Fellow at this year’s conference in Seattle, USA.

It is with great sadness that IDDO has learnt of the passing of Professor Mamadou Pathé Diallo, a valued member of the IDDO team since 2019. Professor Diallo had been a Professor of Paediatrics since 1988 and was the Head of the Medical Centre & Health Counselling (CEMECO) in Kipé, the Paediatric, H...

It was great to welcome researchers Dr Vijayakumar Balakrishnan (ICMR-VCRC), Dr Hemant Mahajan (ICMR-RMRIMS) to IDDO to update on their work across malaria, visceral leishmaniasis, and filariasis. IDDO is building a partnership with the Indian Council of Medical Research (ICMR) to exchange and sh...

IDDO’s Medicine Quality Research Group delivered in-person training to researchers in Mozambique and Ghana to support a study into the quality of three antibiotics.

Come and meet us at this year’s ASTMH 71st Annual Meeting - the first fully in-person meeting since 2019. Thousands of delegates are expected to attend with leading global health researchers from more than 111 countries around the world. During the conference we have several posters, talks, meetings...

Join IDDO and WWARN Director, Professor Philippe Guérin at this year’s RSTMH’s Annual Meeting where he will be discussing topical issues in malaria and in resistance with a wide range of speakers and panellists.

A new WWARN study, published in BMC Medicine, provided evidence for a World Health Organization (WHO) recommendation that a single primaquine target dose of 0.25 mg/kg is generally safe and well tolerated when given together with an ACT to treat malaria. 

In the first published study of its kind, a new WWARN paper in the Malaria Journal has created near-real-time maps to support antimalarial drug resistance monitoring, using routine malaria surveillance data and individually patient linked data on molecular markers of antimalarial drug resistance.

New studies suggest that substandard and falsified (SF) antimicrobials, in particular antibiotics, are widely spread with higher prevalence in low-and middle-income countries (LMIC). The quality of the evidence available in the scientific literature is poor but the issue has significant risks for On...

Researchers have created a mathematical model to predict genetic resistance to antimalarial drugs in Africa to manage one of the biggest threats to global malarial control.

The Medicine Quality Research Group organised a multidisciplinary hybrid meeting at Keble College, Oxford, July 3 to 6, for the FORESFA project ‘Forensic epidemiology and impact of substandard and falsified antimicrobials on public health’, funded by a Wellcome Collaborative Award.